FGF21 Emerges as Next Strategic Layer in Cardiometabolic Market Beyond GLP-1
Event summary
- $10.7 billion in recent acquisitions and licensing activity signals growing confidence in FGF21 as the next major opportunity beyond GLP-1.
- PatentVest's report highlights how leading pharmaceutical companies are positioning themselves for the next phase of obesity innovation.
- FGF21 is increasingly being developed alongside—not instead of—GLP-1 therapies to address broader cardiometabolic disease.
- The report analyzes competitive landscape, intellectual property strategies, and clinical programs shaping the emerging FGF21 market.
The big picture
The obesity market is evolving beyond first-generation GLP-1 therapies as pharmaceutical companies invest in complementary approaches designed to address liver disease, lipid metabolism, chronic inflammation, and other cardiometabolic conditions. The $10.7 billion in recent acquisitions and licensing activity underscores the growing confidence in FGF21 as the next major opportunity, reshaping the strategic landscape of obesity therapeutics.
What we're watching
- Competitive Dynamics
- How the strategic positioning of Novo Nordisk, Roche, and GSK will influence the long-term competitive landscape in the FGF21 market.
- Intellectual Property Strategy
- Whether evolving patent strategies for combination therapies will shape the future of obesity therapeutics.
- Market Expansion
- The pace at which FGF21 therapies will be integrated with GLP-1 treatments to address broader cardiometabolic conditions.
Related topics